This clinical study is designed to evaluate the safety and efficacy of oral administration of the food additive colostrum derived antibodies to Clostridium difficile for prevention of Clostridium difficile associated disease (CDAD).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Daily administration of Colostrum derived antibodies against C. difficile.
Hadassah Medical Organization
Jerusalem, Israel
Recurrence of active Clostridium difficile associated diarrhea in index cases
Time frame: 60 days
New cases of Clostridium difficile associated diarrhea in close hospital contacts.
Time frame: 60 days
Disease severity - duration, maximal intensity (number of stools) in index cases.
Time frame: 60 days
Eradication of Clostridium difficile from stools
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.